- AbbVie and Genmab pipeline updates and regulatory engagement
- AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Genmab
Danish healthcare company
-
Nxera Pharma
company in Tokyo, Japan
Nothing else this week.
Related events
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- AbbVie reached an agreement for a drug in Canada.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- AbbVie and Eli Lilly are competing in the pharmaceutical market.